Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Prestige Consumer Healthcare Price Performance
Shares of NYSE:PBH opened at $59.35 on Monday. The company has a market cap of $2.96 billion, a P/E ratio of 14.87, a P/E/G ratio of 1.77 and a beta of 0.50. The company has a quick ratio of 1.21, a current ratio of 2.09 and a debt-to-equity ratio of 0.93. Prestige Consumer Healthcare has a 52 week low of $51.70 and a 52 week high of $63.83. The business has a fifty day simple moving average of $57.68 and a 200-day simple moving average of $56.62.
Prestige Consumer Healthcare (NYSE:PBH - Get Rating) last issued its earnings results on Thursday, May 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.02. The firm had revenue of $266.94 million for the quarter, compared to analysts' expectations of $258.25 million. Prestige Consumer Healthcare had a return on equity of 13.27% and a net margin of 18.53%. The firm's revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.79 earnings per share. Equities research analysts forecast that Prestige Consumer Healthcare will post 4.19 EPS for the current year.
Wall Street Analyst Weigh In
PBH has been the subject of several recent research reports. Jefferies Financial Group raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating and raised their price target for the stock from $65.00 to $70.00 in a research report on Tuesday, May 10th. Oppenheimer raised Prestige Consumer Healthcare from a "market perform" rating to an "outperform" rating and set a $63.00 price target for the company in a research report on Monday, May 9th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $80.50.